Introduction {#s01}
============

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide ([@bib1]). Multiple risk factors influence the development of CRC, including age, genetics, lifestyle, diet, and environmental factors ([@bib86]; [@bib7]). Unlike many other types of cancers that develop in a relatively sterile environment, CRC occurs at the largest interface between host and gut microbial communities and is often associated with an inflammatory response. Chronic inflammatory diseases of the intestinal tract, such as inflammatory bowel disease (IBD), increase the risk for the development of CRC, an association that has been termed colitis-associated CRC (CAC; [@bib34]). Inflammation enhances the development of CAC by various mechanisms, including the development of a genotoxic environment, as well as expression of proinflammatory cytokines and prostaglandins that promote cellular survival, angiogenesis, and other aspects of the neoplastic process ([@bib7]; [@bib52]).

Several studies have reported an association between CRC and changes of the overall community structure of the gut microbiota ([@bib101]; [@bib108]; [@bib28]). Furthermore, distinct commensal bacteria, such as *Fusobacterium* spp., can be found in the microenvironment of tumors, and have been shown in experimental models to promote tumor development in genetically predisposed animals ([@bib15]; [@bib48]; [@bib94]; [@bib86]; [@bib98]). These observations have generated interest in investigating how gut microbes are involved in CRC development.

The carcinogenic effects of commensal gut bacteria can involve direct effects of bacteria-derived products. An example of this mechanism involves a small number of bacteria that have been shown to secrete carcinogenic compounds, such as colibactin, a polyketide-derived genotoxin produced by Enterobacteriaceae ([@bib74]; [@bib8]; [@bib73]; [@bib76]; [@bib103]). While Enterobacteriaceae are considered to be a part of the "core microbiota" shared by the majority of humans ([@bib60]; [@bib71]; [@bib54]), specific members of the Enterobacteriaceae family, in particular *Escherichia coli* (phylogroups B2 and D), *Klebsiella* spp., and *Proteus mirabilis* are frequently detected and overrepresented in the microbiota of CRC patients ([@bib20]; [@bib93]; [@bib58]). Exposure of mammalian cells to colibactin induces interstrand DNA cross-linking ([@bib99]; [@bib5]; [@bib103]) and triggers the ataxia telangiectasia mutated signaling pathway ([@bib66]; [@bib57]; [@bib18]). Activation of this damage response results in G2-M cell cycle arrest ([@bib33]). Expression of colibactin biosynthesis genes is highly induced in biopsies from human CRC patients ([@bib24]). Consistent with a role of colibactin in tumor induction, experimental administration of a colibactin-producing *E. coli* strain favors tumor development in an animal model of inflammation-associated CRC, while *E. coli* mutants deficient for producing colibactin fail to do so ([@bib2]; [@bib77]).

In addition to the release of genotoxin, the gut microbiota can enhance CRC development through its role on tumor-associated inflammation, with cytokines and other inflammatory products magnifying the neoplastic process. Bacteria are known to penetrate tumor tissues and directly enhance inflammation ([@bib21]). Furthermore, intestinal inflammation promotes dysbiotic changes in the microbiota composition. In particular, Enterobacteriaceae populations expand during bouts of inflammation ([@bib55]; [@bib30]). The outgrowth of these pathobionts in turn exacerbates intestinal inflammation, epithelial cell damage, and wound repair responses ([@bib13]; [@bib35]; [@bib44]; [@bib72]), thus amplifying known risk factors of CAC development.

*E. coli* and other members of the Enterobacteriaceae family are among the most overrepresented bacteria in IBD and CAC ([@bib93]; [@bib58]; [@bib62]). Currently there are few experimental approaches that attempt to restrict colonization with genotoxin-producing Enterobacteriaceae members. Oral antimicrobial therapy with broad-spectrum antibiotics is suitable to temporarily reduce the abundance of certain protumoral bacterial species. However, broad-spectrum antimicrobial therapy also removes beneficial microbes and increases the risk of pathogen expansion ([@bib92]; [@bib17]; [@bib27]).

To overcome the limitations that broad-spectrum antibiotics have in this setting, we recently developed a strategy that targets the unique metabolic capabilities of Enterobacteriaceae ([@bib107]; [@bib40]). During episodes of inflammation, Enterobacteriaceae rely on nitrate respiration and formate oxidation, while these metabolic pathways are inactive during homeostatic conditions ([@bib107]; [@bib40]). *E. coli* expresses three nitrate reductases and two respiratory formate dehydrogenases to facilitate this disease-associated metabolism ([@bib96]). All of these enzymes are metalloenzymes with a molybdenum cofactor (MoCo) in their active site ([@bib26]). In the presence of excess amounts of tungsten ions (W), tungsten is incorporated into the molybdopterin cofactor ([@bib64]). This tungsten-substituted cofactor is inactive in Enterobacteriaceae and thus MoCo-dependent enzymes are selectively inhibited by tungsten in vitro ([@bib26]; [@bib31]). Administration of tungstate, a water-soluble tungsten salt, ameliorates dysbiosis and intestinal inflammation in acute colitis models ([@bib114]). Here, we investigated whether administration of tungstate could reduce *E. coli*--driven tumorigenesis using mouse models of chronic inflammation and CAC.

Results {#s02}
=======

Tungstate treatment blunts expansion of commensal *E. coli* in a mouse model of chronic inflammation {#s03}
----------------------------------------------------------------------------------------------------

To investigate the role of commensal Enterobacteriaceae in the development of CAC, we experimentally introduced the *E. coli* strain MP13 into the azoxymethane (AOM)/dextran sulfate sodium (DSS) model of CAC ([Fig. 1 A](#fig1){ref-type="fig"}). MP13 is a tetracycline-resistant derivative of the murine commensal *E. coli* strain MP1 ([@bib51]) and was used to facilitate culture-dependent quantification in the intestinal content and the feces. The MP1 genome does not encode the genes required for biosynthesis of colibactin ([@bib51]). C57BL/6 mice were treated with a one-time i.p. injection of AOM (20 mg/kg). No Enterobacteriaceae family members were detected in the feces of these animals as determined by growth on MacConkey agar plates. 1 wk later, mice received oral streptomycin treatment to facilitate engraftment of *E. coli* MP13, and after 48 h, mice were intragastrically inoculated with *E. coli*. Mice were then treated with 2% DSS in the drinking water for 1 wk or mock treated with water, followed by a recovery phase of 2 wk on regular drinking water. The injury was repeated a total of three times. Fecal samples were obtained after DSS-induced colitis episodes ("flares") and at the completion of the recovery period. Animals were euthanized after the third recovery phase, and the bacterial load of MP13 in the feces was determined ([Fig. 1 B](#fig1){ref-type="fig"}). *E. coli* MP13 colonized mock-treated mice at a consistently low level throughout the time course. In contrast, induction of gut inflammation by DSS resulted in a pronounced expansion of the *E. coli* MP13 population, reaching more than three orders of magnitude compared with mock-treated mice during each flare. This population contracted during recovery phases and expanded upon repeated induction of inflammation ([Fig. 1 B](#fig1){ref-type="fig"}).

![**Impact of tungstate treatment on gut microbial communities during chronic inflammation.** Groups of C57BL/6 mice were treated i.p. with 20 mg/kg AOM. After 7 d, animals received streptomycin (Strep; 2 mg/ml in the drinking water) and were intragastrically inoculated with *E. coli* MP13 2 d later. Mice were treated for 1 wk with 2% DSS (*n* = 15), 2% DSS supplemented with 0.2% sodium tungstate (W, *n* = 18), or filtered drinking water (mock, *n* = 5). Animals were allowed to recover for 2 wk, with the tungsten-treated group receiving 0.2% sodium tungstate throughout the experiment. Injury was repeated two more times. One group of animals received tungstate exclusively during DSS treatment (W~(Tx)~, *n* = 9). Another group received DSS but was not colonized by MP13 (*n* = 6). At predetermined time points, feces were collected, and tissues were harvested 73 d after AOM treatment. Two independent experiments were performed and are shown in B; C--E show results from one of these experiments. **(A)** Schematic representation of the experimental design. **(B)** Burden of *E. coli* MP13 in the feces and colon content at the indicated time points determined by plating on selective media. LOD, limit of detection. Bars represent the geometric mean ± 95% confidence interval. P values were calculated by two-way ANOVA and a post hoc Tukey's multiple comparison test on log-transformed data. **(C)** Principal coordinate analysis (PCoA) of the gut microbiota composition, as determined by 16S rDNA amplicon sequencing. DSS-treated, red circles; DSS+W--treated, blue circles. Data from each mouse are linked by a colored line. **(D)** Bacterial phyla that were significantly enriched in indicated groups identified by linear discriminant analysis (LDA) effect size measurements. **(E)** Comparison of gut microbiota composition at the class level in DSS-treated and DSS+W--treated mice. Bars represent the mean ± 95% confidence interval. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, not statistically significant.](JEM_20181939_Fig1){#fig1}

Since *E. coli* and other Enterobacteriaceae rely on MoCo-dependent metabolic pathways, such as nitrate respiration, to bloom during intestinal inflammation ([@bib107]; [@bib40]), we examined whether these pathways played a role in *E. coli* population expansion in the AOM/DSS colitis model. We inoculated mice with an equal ratio of the *E. coli* (Nissle 1917) wild-type strain and an isogenic mutant deficient in MoCo biosynthesis (*moaA* mutant) as indicators of microbial metabolism (Fig. S1 A), a strategy we had validated in previous reports ([@bib107]; [@bib40]). In the absence of inflammation, the wild-type strain and the *moaA* mutant were recovered at comparable levels on day 17 (Fig. S1 B). In contrast, the wild-type strain outcompeted the *moaA* mutant in DSS-treated mice. Similar results were obtained for a mutant deficient for all three nitrate reductase enzymes (Fig. S1 B). These findings provide support for the idea that MoCo-dependent processes are dispensable under homeostatic conditions, but are critical for *E. coli* fitness during episodes of gut inflammation.

Enterobacterial molybdoenzymes can be inhibited by soluble tungsten salts ([@bib114]). Consistent with a role for these metabolic pathways in *E. coli* expansion, administration of 0.2% sodium tungstate in the drinking water blunted the expansion of *E. coli* MP13 in all flare and recovery phases throughout the 73-d time course ([Fig. 1 B](#fig1){ref-type="fig"}). Moreover, the Nissle 1917 wild-type strain and the *moaA* mutant were recovered at similar levels on day 17 when mice were concurrently treated with DSS and 0.2% sodium tungstate in the drinking water (Fig. S1 B), suggesting that our experimental administration of tungstate was sufficient to inhibit bacterial molybdoenzymes in the intestinal tract. No overt negative effects of long-term tungstate treatment on the murine host were noted. We had previously shown that mice exposed to 0.2% tungstate in the drinking water do not exhibit liver damage ([@bib114]). Oral administration of 100 mg sodium tungstate twice daily for the duration of 8 wk as part of a clinical trial did not reveal any overt signs of toxicity in humans ([@bib38]).

Tungstate treatment specifically targets Gammaproteobacteria in the dysbiotic gut microbiota {#s04}
--------------------------------------------------------------------------------------------

We next sought to explore the impact of long-term oral tungstate treatment on gut microbial communities. We extracted DNA from feces collected before AOM treatment (naive) and at the end of the second flare (day 38) and from colon content at the end of the experiment (day 73), and determined the composition of the bacterial microbiota by 16S rDNA amplicon sequencing ([Fig. 1, C--E](#fig1){ref-type="fig"}; and Fig. S1, C--H). Communities in both treatment groups were very similar at the onset of the experiment, as indicated by principal coordinate analysis ([Fig. 1 C](#fig1){ref-type="fig"}). Beta diversity analysis revealed that repeated DSS treatment irreversibly shifted the microbiota structure toward a dysbiotic state ([Figs. 1 C](#fig1){ref-type="fig"} and S1 C). Population analysis of similarity (ANOSIM) showed significant differences of communities in DSS-treated mice between the naive and in-flare time points (*R* = 0.89, P = 0.002) and naive and recovery time points (*R* = 0.90, P = 0.001; [Fig. 1 C](#fig1){ref-type="fig"}). This finding was further supported by UniFrac distance analysis (Fig. S1 C). Linear discriminative analysis effect size of communities revealed a marked overrepresentation of Proteobacteria in DSS-treated mice ([Fig. 1 D](#fig1){ref-type="fig"}). When mice were treated simultaneously with DSS and tungstate, microbial dysbiosis was significantly reduced compared with DSS-only treatment (DSS+W treatment naive vs. flare, ANOSIM *R* = 0.69, P = 0.001; [Figs. 1 C](#fig1){ref-type="fig"} and S1 C). Similarly, tungstate treatment reduced the severity of dysbiosis during the recovery phase (DSS+W treatment naive vs. recovery; ANOSIM *R* = 0.53, P = 0.001; [Figs. 1 C](#fig1){ref-type="fig"} and S1 C). Oral tungstate administration blunted the expansion of facultative anaerobic Gammaproteobacteria during chronic inflammation and led to a limited compensatory increase in the relative abundance of facultative anaerobic Bacilli ([Figs. 1 E](#fig1){ref-type="fig"} and S1, D--H). We had previously shown that oral administration of 0.2% tungstate does not alter the composition of the gut microbiota in the absence of inflammation ([@bib114]). Collectively, these data demonstrate that the inflammation-associated bloom of Gammaproteobacteria in the AOM/DSS colitis model can be selectively inhibited by oral administration of tungstate.

Oral administration of sodium tungstate treatment reduces intestinal inflammation and tumorigenesis {#s05}
---------------------------------------------------------------------------------------------------

We reasoned that by controlling repeated blooms of Enterobacteriaceae, tungstate treatment could improve chronic intestinal inflammation and thus prevent tumor formation. We therefore analyzed normalized colon length, mRNA levels of a panel of proinflammatory markers in the distal colon, animal body weight, and pathological changes in the colonic tissue ([Figs. 2 A](#fig2){ref-type="fig"} and S2, A--D). DSS-treated mice, precolonized with MP13, exhibited shorter normalized colon length and increased mRNA levels of proinflammatory markers in the colon tissue compared with mock-treated, MP13-colonized mice ([Figs. 2 A](#fig2){ref-type="fig"} and S2, A--D). Mice that were only treated with AOM and *E. coli* MP13 exhibited a small number of tumors, while induction of colitis with DSS resulted in significantly increased tumor incidence ([Fig. 2, B and C](#fig2){ref-type="fig"}). When we treated mice that were free of any detectable Enterobacteriaceae family members with AOM and DSS alone, the number of tumors was significantly lower compared with *E. coli* MP13-colonized mice treated with AOM/DSS ([Fig. 2, B and C](#fig2){ref-type="fig"}). Since the *E. coli* MP13 genome does not encode genes required for colibactin biosynthesis, this finding suggests that commensal *E. coli* strains could aggravate tumorigenesis through colibactin-independent processes.

![**Analysis of tumorigenesis in the AOM/DSS colitis model.** Tissue was obtained from the animals described in [Fig. 1](#fig1){ref-type="fig"} (73 d after AOM treatment). Animals were initially treated with AOM and colonized with the *E. coli* MP13 wild-type strain, as indicated. Groups received filtered drinking water (mock; white bars, *n* = 5), 2% DSS (black bars, *n* = 15), or 2% DSS + 0.2% sodium tungstate (gray bars, *n* = 18). Subsets of the animals received tungstate exclusively during DSS-induced flares (W~(Tx)~, *n* = 9; gray dash pattern) or received DSS but were not colonized by MP13 (black dash pattern, *n* = 6). Data from two independent experiments are shown. **(A)** Colon length was normalized to the total body weight of each animal. White dots represent data from individual animals. **(B)** Tumor incidence in the large intestine. **(C)** Gross pathology of the distal colon. Scale bars represent 1 mm. **(D)** Representative images of H&E-stained colonic sections. Scale bars represent 250 µm. **(E)** Tumor area as determined by a morphometric analysis. White dots represent data from individual animals. Bars represent the geometric mean ± 95% confidence interval. P values were calculated by unpaired, two-tailed Student's *t* test on log-transformed data. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181939_Fig2){#fig2}

Oral administration with sodium tungstate during flares and recovery phases consistently reduced markers of intestinal inflammation in the colon tissue ([Figs. 2 A](#fig2){ref-type="fig"} and S2, A--D), although in some cases these trends did not reach statistical significance. Importantly, coadministration of AOM/DSS and tungstate to MP13-colonized mice significantly reduced tumor incidence ([Fig. 2, B and C](#fig2){ref-type="fig"}) and tumor area ([Fig. 2, D and E](#fig2){ref-type="fig"}).

In the previous set of experiments, tungstate was administered throughout all flare and recovery phases. To better mimic a potential treatment regimen in patients with reoccurring flare-ups, we administered 0.2% sodium tungstate only during the DSS-induced flares (W~(Tx)~; [Fig. 1 A](#fig1){ref-type="fig"}). Therapeutic administration of tungstate was effective in blunting expansion of MP13 ([Fig. 1 B](#fig1){ref-type="fig"}), in improving colon length shortening ([Fig. 2 A](#fig2){ref-type="fig"}), and in reducing the tumor incidence in the large intestine ([Fig. 2 B](#fig2){ref-type="fig"}).

We also considered whether tungstate could prevent tumorigenesis in mice with a native microbiota ([Fig. 3](#fig3){ref-type="fig"} and Fig. S2 E). We thus purchased C57BL/6 mice from a commercial vendor (Charles River Laboratories). These animals naturally harbor Enterobacteriaceae family members ([@bib40]). Groups of AOM-treated animals received either DSS or DSS + 0.2% sodium tungstate ([Fig. 1 A](#fig1){ref-type="fig"}). Colonization by Enterobacteriaceae family members was quantified by plating fecal material and colon content (day 73) on MacConkey agar plates ([Fig. 3 A](#fig3){ref-type="fig"}). Akin to our previous findings, tungstate treatment reduced the overall burden of Enterobacteriaceae family members ([Fig. 3 A](#fig3){ref-type="fig"}) and tumor incidence in the large intestine ([Fig. 3, B and C](#fig3){ref-type="fig"}).

![**Contribution of the native gut microbiota to tumorigenesis in the AOM/DSS colitis model.** Mice harboring endogenous Enterobacteriaceae were treated with AOM and DSS as described in [Fig. 1](#fig1){ref-type="fig"}, except that the antibiotic treatment and colonization with *E. coli* was omitted. Tissue was obtained 73 d after AOM treatment. Groups received either 2% DSS (*n* = 10, black bars) or 2% DSS + 0.2% sodium tungstate (*n* = 11, gray bars). Data from one experiment are shown. **(A)** The burden of Enterobacteriaceae in the feces and in the colon content at the indicated time points was determined by plating on MacConkey agar plates. Bars represent the geometric mean ± 95% confidence interval. P values were calculated by two-way ANOVA and a post hoc Tukey's multiple comparison test on log-transformed data. **(B)** Tumor incidence in the colon. Bars represent the median ± interquartile range. P values were calculated by two-tailed Mann--Whitney *U* test. **(C)** Representative images of the distal colon. Scale bars represent 1 mm. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181939_Fig3){#fig3}

Taken together, these experiments demonstrate that manipulation of the gut microbiota composition by sodium tungstate reduces gut microbiota dysbiosis, dysbiosis-associated inflammation, and tumorigenesis in the AOM/DSS colitis model.

Tungstate reduces colibactin-driven tumorigenesis {#s06}
-------------------------------------------------

Colibactin-producing *E. coli* strains potentiate tumorigenesis in mouse models of CAC ([@bib2]). We investigated whether tungstate treatment would decrease colonization by a murine-adapted, colibactin-producing *E. coli* (NC101) and thus decrease colibactin-driven CAC. To this end, we colonized groups of AOM-treated C57BL/6 mice with the *E. coli* NC101 wild-type strain or an isogenic mutant deficient for biosynthesis of colibactin (Δ*pks* mutant), respectively ([Fig. 1 A](#fig1){ref-type="fig"}). To assist with quantification in fecal material, both strains carried the low-copy number plasmid pWSK29 encoding a β-lactamase. Animals were treated with DSS or DSS + 0.2% sodium tungstate as described above ([Fig. 1 A](#fig1){ref-type="fig"}). The NC101 wild-type strain and the Δ*pks* mutant were recovered from the feces at similar levels throughout the time course, with populations expanding during inflammatory flares and decreasing during recovery ([Fig. 4 A](#fig4){ref-type="fig"}). Tumor incidence, determined on day 73, was infrequent in mice that were inoculated with NC101 and received only regular drinking water ([Fig. 4, B and C](#fig4){ref-type="fig"}). Repeated induction of colitis (AOM/DSS colitis model) of mice colonized with the NC101 wild-type strain resulted in elevated tumor incidence. In the NC101-colonized as well as the MP1-colonized mice (AOM/DSS colitis model), multifocal neoplastic proliferations in the mucosa, expansive, noninvasive, and nonencapsulated lesions were noted. Neoplastic cells were arranged predominantly in tubules, supported by a moderate amount of lamina propria--like fibrovascular tissue and composed of columnar epithelial cells with well-aggregated pseudostratified appearance. There was moderate cellular anisocytosis and nuclear pleomorphism, with an average of one to two mitotic figures per high-magnification field. Moderate focally extensive inflammation in the stromal tissue, composed of neutrophils and histiocytes, was observed, and most of the epithelium that covered the proliferation was ulcerated with mild neutrophilic infiltration. In some instances, focally extensive areas of enterocyte loss and necrosis, with abundant neutrophilic inflammatory infiltrate and exudation, with debris and regenerative glandular epithelium in adjacent mucosa were noted (Table S1 and [Fig. 2 D](#fig2){ref-type="fig"}).

![**Effect of oral sodium tungstate administration on genotoxin-producing *E. coli* populations and tumorigenesis in the AOM/DSS colitis model.** Groups of C57BL/6 mice were treated i.p. with AOM. After 7 d, streptomycin-pretreated animals were intragastrically inoculated with the *E. coli* NC101 wild-type or an isogenic Δ*pks* mutant (*n* = 8). Groups were then treated for 1 wk with 2% DSS (*n* = 29), 2% DSS supplemented with 0.2% sodium tungstate (W, *n* = 32), or filtered drinking water (mock, *n* = 10) as indicated. Animals were allowed to recover for 2 wk, with the tungsten-treated group receiving 0.2% sodium tungstate throughout the experiment. Injury was repeated two more times. At predetermined time points, feces were collected, and tissues were harvested 73 d after AOM treatment. See [Fig. 1 A](#fig1){ref-type="fig"} for a schematic representation. Data from five independent experiments are shown. **(A)** Burden of NC101 in the feces and the colon content at various time points determined by a culture-dependent method. The dotted line indicates the limit of detection (LOD). Bars represent the geometric mean ± 95% confidence interval. P values were calculated by two-way ANOVA and a post-hoc Tukey's multiple comparison test on log-transformed data. ns, not significant. **(B)** Representative images of gross pathology of the distal large intestine. Scale bars represent 1 mm. **(C)** Tumor incidence in the large intestine. Each dot represents of one animal. Bars indicate the median and the interquartile range. P values were calculated by two-tailed Mann--Whitney *U* test. **(D)** Correlation between the NC101 population size (mean of three flares) and the tumor incidence at the end of the experiment. Each dot represents one animal; the color of the dot indicates the treatment. The Spearman's rank correlation coefficient is indicated, and a linear trendline is shown (P \< 0.001). \*, P \< 0.05; \*\*, P \< 0.01, \*\*\*, P \< 0.001; ns, not statistically significant.](JEM_20181939_Fig4){#fig4}

Consistent with a previous report ([@bib2]), mice colonized with the Δ*pks* mutant exhibited significantly decreased tumor incidence compared with mice colonized with the wild-type strain (P \< 0.05; 29% decrease). Tungstate treatment significantly decreased NC101 intestinal burden ([Fig. 4 A](#fig4){ref-type="fig"}). Importantly, administration of tungstate significantly lowered tumor incidence in mice colonized with the *E. coli* NC101 wild-type strain in the AOM/DSS colitis model by ∼64% (P \< 0.001; [Fig. 4, B and C](#fig4){ref-type="fig"}). NC101 populations in the gut lumen directly correlated with tumor incidence ([Fig. 4 D](#fig4){ref-type="fig"}). Notably, the effect size of tungstate treatment was more pronounced (64% reduction) than the effect mediated by genetic ablation of colibactin production (29% reduction), suggesting that tungstate decreases tumor formation by both ameliorating inflammation and reducing the burden of genotoxin-producing bacteria. Tungstate treatment had no discernable effect on tumor size and histological features (Table S1).

Tungstate treatment decreases DNA damage and intestinal inflammation in a model of colibactin-driven CAC {#s07}
--------------------------------------------------------------------------------------------------------

A subset of colibactin-producing *E. coli* strains, so-called adherent invasive *E. coli* strains (AIECs), have been isolated from areas of inflamed intestinal tissue in patients with Crohn's disease ([@bib20]). These AIEC strains colonize the mucosa by adhering to the intestinal epithelium ([@bib20]), where local release of colibactin can induce DNA damage in host cells ([@bib2]; [@bib103]). Furthermore, colibactin production is coregulated with siderophore biosynthesis under iron-limiting conditions, such as intestinal inflammation ([@bib59]; [@bib29]; [@bib95]).

We next investigated whether tungstate treatment would deplete colibactin-producing *E. coli* strain from the mucosal interface, thus reducing inflammation and DNA damage. Animals were colonized with NC101 and treated with AOM and DSS as described above, and samples were analyzed 38 d after AOM treatment ([Fig. 5 A](#fig5){ref-type="fig"}). Mirroring our initial findings with MP13 ([Figs. 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), tungstate treatment of NC101-colonized animals improved intestinal inflammation, as determined by histopathology, mRNA levels of inflammatory marker genes, and colon length ([Fig. 5, B--D](#fig5){ref-type="fig"}; and Fig. S3). Tungstate had no discernable effect on animal body weight (Fig. S3 D).

![**Analysis of DNA damage and intestinal inflammation. (A)** Groups of C57BL/6 mice were treated i.p. with 20 mg/kg AOM. After 7 d, animals received streptomycin (2 mg/ml in the drinking water) and were intragastrically inoculated with the colibactin-producing *E. coli* NC101 2 d later. Mice were treated for 1 wk with either 2% DSS (black bars) or 2% DSS supplemented with 0.2% sodium tungstate (W; gray bars). Animals were allowed to recover for 2 wk, with the tungsten-treated group receiving 0.2% sodium tungstate throughout the experiment. After 38 d, samples of the colon were obtained. Data from two independent experiments are shown. **(B--D)** H&E-stained sections were scored by a veterinary pathologist for epithelial damage, polymorphonuclear neutrophil infiltration, submucosal edema, and exudate in the lumen. DSS group: *n* = 7; DSS+W group: *n* = 8. **(B)** Combined histopathology score. Bars indicate the median and the interquartile range. P values were calculated by two-tailed Mann--Whitney *U* test. **(C and D)** Representative images of H&E-stained sections of the proximal (C) and distal (D) colon. Scale bars represent 100 µm. **(E--G)** Transverse sections of colonic tissues were stained for *E. coli* (red), DNA damage using γ-H2AX foci as marker (green), and cell nuclei (blue). Individual image tiles were assembled to quantify *E. coli* burden and number of γ-H2AX--positive cells and total mammalian cells. Both groups: *n* = 4. **(E)** Representative images. Scale bars represent 500 µm. **(F)** Burden of *E. coli* normalized to the number of mammalian cells. **(G)** Abundance of γ-H2AX--positive cells normalized to the number of all mammalian cells. For F and G, P values were calculated by unpaired, two-tailed Student's *t* test on log-transformed data. Bars represent the geometric mean ± 95% confidence interval. \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20181939_Fig5){#fig5}

We visualized *E. coli* via fluorescence in situ hybridization, and colibactin-induced DNA damage was assessed through immunofluorescence staining of phospho-γ-H2AX ([@bib87]). Transversal sections of colonic tissue were imaged in independent tiles and reassembled as described in [@bib25] ([Fig. 5, E--G](#fig5){ref-type="fig"}). We observed *E. coli* NC101 bacteria in proximity to the mucosa and notable cellular DNA damage in the gut epithelial tissue in DSS-treated mice. *E. coli* numbers and DNA damage were reduced in mice receiving both DSS and tungstate ([Fig. 5, E--G](#fig5){ref-type="fig"}). Similar observations were made at the 73-d time point (Fig. S4, A--C).

Furthermore, we determined the effect of tungsten on DNA damage response and cell cycle progression ex vivo in intestinal epithelial cells ([Fig. 6](#fig6){ref-type="fig"}). Animals were treated as described above ([Fig. 6 A](#fig6){ref-type="fig"}), colonocytes were isolated after 21 d, and relative transcription of a panel of genes was determined by quantitative RT-PCR ([Fig. 6, B--D](#fig6){ref-type="fig"}). In the AOM/DSS model, transcription of the tumor suppressor p53 (encoded by *Trp53*) and genes involved in DNA damage response is down-regulated ([@bib112]; [@bib88]). Consistent with these previous reports, *Trp53, Ercc1*, and *Mlh1* mRNA levels were decreased in AOM/DSS-treated mice that had been colonized with NC101 animals ([Fig. 6, B and C](#fig6){ref-type="fig"}). Importantly, transcription of *Ercc1*, *Mlh1*, and *Trp53* was rescued in tungsten-treated animals. Similarly, tungstate rescued transcription of genes involved in cell cycle progression, such as *Cdk4*, *Cdk6*, and *Ccnd1* ([Fig. 6 D](#fig6){ref-type="fig"}). Collectively, these data suggest that tungsten impacts tumorigenesis through at least two mechanisms, i.e., by decreasing mucosal inflammation and by reducing DNA damage at early time points.

![**Impact of oral sodium tungstate treatment on cell cycle progression and DNA damage response in the AOM/DSS model.** Groups of C57BL/6 mice were treated i.p. with 20 mg/kg AOM. After 7 d, animals received streptomycin (2 mg/ml in the drinking water) and were intragastrically inoculated with the colibactin-producing *E. coli* NC101 2 d later. Mice were treated for 1 wk with 2% DSS (*n* = 14), 2% DSS supplemented with 0.2% sodium tungstate (DSS+W, *n* = 13), or filtered drinking water (mock, *n* = 5). Animals were allowed to recover for 4 d. Colonocytes were isolated, total RNA was extracted, and relative mRNA levels of marker genes were determined by quantitative RT-PCR. Data from two independent experiments are shown. **(A)** Schematic representation of the experiment. **(B)** mRNA levels of *Ercc1* and *Mlh1*, whose gene products are involved in DNA damage response. **(C)** mRNA levels of *Trp53*, encoding the tumor suppressor p53. **(D)** mRNA levels of *Cdk4*, *Cdk6*, and *Ccnd1*, whose products are involved in cell cycle progression. Bars represent the geometric mean ± 95% confidence interval. P values were calculated by unpaired, two-tailed Student's *t* test on log-transformed data. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181939_Fig6){#fig6}

Tungstate treatment reduces polyp formation in an *Il10*-deficient mouse model, but not in *Apc^Min^*^+/−^ mice {#s08}
---------------------------------------------------------------------------------------------------------------

Inflammation in the DSS colitis model is a response to epithelial injury. To exclude the possibility that the observed effects of tungstate on tumorigenesis were unique to DSS-induced colitis, we used a genetic model of gut inflammation. *Il10*-deficient mice spontaneously develop colitis, a process that can be accelerated by the administration of the nonsteroidal antiinflammatory drug piroxicam ([@bib37]). Groups of *Il10*-deficient mice were treated i.p. with AOM (20 mg/kg). 1 wk later, streptomycin (2 mg/ml) was administered in the drinking water, followed 2 d later by intragastric inoculation with *E. coli* NC101. Piroxicam-supplemented diet (100 ppm) was given until the end of the experiment 38 d after the initial AOM injection. One group received normal drinking water while the other group was supplemented with 0.02% sodium tungstate ([Fig. 7 A](#fig7){ref-type="fig"}). Tungstate administration significantly decreased the burden of *E. coli* NC101 in the colon content by three orders of magnitude ([Fig. 7 B](#fig7){ref-type="fig"}). The microbiota composition in the two groups (piroxicam vs. piroxicam + tungstate) was significantly different (ANOSIM \[unweighted UniFrac\]: *R* = 0.2659, P = 0.003), as determined by 16S rDNA amplicon sequencing ([Fig. 7 C](#fig7){ref-type="fig"}). As predicted, tungstate significantly depleted Enterobacteriaceae family members in piroxicam-treated *Il10*^−/−^ mice. Curiously, we observed a significant decrease in the abundance of members of the phylum Verrucomicrobia ([Fig. 7 C](#fig7){ref-type="fig"}). Water-treated mice displayed a large number of colonic polyps (median = 22.5), while tungstate treatment in the drinking water significantly reduced inflammatory markers and polyp formation in this model (median = 14; P \< 0.05; [Fig. 7, D and E](#fig7){ref-type="fig"}; and Fig. S4 D). This experiment lends further support to the idea that reducing colonization with genotoxin-producing *E. coli* through oral treatment with tungstate prevents CAC.

![**Impact of oral sodium tungstate treatment on *E. coli* populations and tumorigenesis in AOM-treated *Il10*-deficient mice.** Groups of *Il10*-deficient mice on the C57BL/6 background were injected i.p. with AOM, treated with streptomycin (Strep), and then colonized with the *E. coli* NC101 wild-type strain. Inflammation was induced by administration of piroxicam in the rodent diet for 4 wk. One group was treated with 0.02% sodium tungstate (Piroxicam+W, *n* = 10) in the drinking water while the other received filtered drinking water (Piroxicam, *n* = 10). Samples were obtained 38 d after AOM injection. Data from two independent experiments are shown. **(A)** Schematic representation of the experimental design. **(B)** Burden of *E. coli* NC101 in the colon content. Bars represent the geometric mean ± 95% confidence interval. P values were calculated by unpaired, two-tailed Student's *t* test on log-transformed data. **(C)** The taxonomic composition of the microbial community in colonic content determined by 16S rDNA amplicon sequencing. **(D)** Representative images of the colon. Scale bars represent 1 mm. **(E)** Tumor incidence in the large intestine. Bars indicate the median and the interquartile range. P values were calculated by two-tailed Mann--Whitney *U* test. \*, P \< 0.05; \*\*\*, P \< 0.001.](JEM_20181939_Fig7){#fig7}

We also tested the effect of tungstate in *Apc^Min+/−^* mice, a model of familial adenomatous polyposis (FAP; Fig. S5). A small subset of gut microbes have been shown to be associated with tumors in this model, such as *Fusobacterium nucleatum* ([@bib14]). In *Apc^Min+/−^* mice and in mouse colitis models, colonization with *F. nucleatum* accelerates tumorigenesis only in mice with preexisting, tumor-promoting mutations ([@bib49]; [@bib80]). Human FAP patients have predominantly colonic adenomas, while *Apc^Min+/−^* mice typically develop numerous polyps in the small intestine and few colonic tumors ([@bib61]; [@bib109]; [@bib49]; [@bib23]). To improve this limitation of the *Apc^Min+/−^* mouse model, we modified published protocols ([@bib49]) and treated *Apc^Min+/−^* mice with DSS for 1 wk before colonization with *F. nucleatum* (Fig. S5 A). One group was treated with 0.02% sodium tungstate in the drinking water throughout the experiment. After 38 d, the number of tumors in the colon was counted. Curiously, we observed ∼23 tumors per animal in the distal portion of the large intestine, yet tungstate treatment had no impact n the number of tumors (Fig. S5, B and C). In a variation of this model, we colonized groups of *Apc^Min+/−^* mice with the *E. coli* strain NC101 to determine whether the presence of this genotoxic *E. coli* strain could modify tumor development in this model (Fig. S5 D). Tungstate treatment in NC101-colonized *Apc^Min+/−^* mice had no effect on the NC101 population size in the colon content (Fig. S5 E) and did not prevent tumor development in the colon (Fig. S5, F and G). Collectively, these findings provide support for our hypothesis that tungstate primarily targets Enterobacteriaceae family members; tumor formation in *Apc^Min+/−^* mice is dependent on gut microbiota members such as *F. nucleatum* and *Bacteroides fragilis* ([@bib109]; [@bib49]; [@bib21]), but not Enterobacteriaceae family members.

Discussion {#s09}
==========

Bacteria in diverse habitats, including the gut microbiota, express molybdoenzymes ([@bib111]; [@bib113]). Proteobacteria tend to encode the highest number of molybdoenzymes ([@bib111]). Many enzymes in the enterobacterial electron transport chain, including nitrate, dimethylsulfoxide, and trimethylamine *N*-oxide reductases, as well as formate dehydrogenases, exhibit a MoCo in their active site. We found that oral tungstate administration during chronic colitis specifically restricts Gammaproteobacteria populations, in particular Enterobacteriaceae family members. This is consistent with the idea that increased availability of respiratory electron acceptors in the gut lumen facilitates a restructuring of the microbial community structure during inflammation ([@bib105]; [@bib10]). In contrast, the effect of tungstate on the abundance of obligate anaerobic gut microbes such as Bacteroidia and Clostridia was very limited in our experimentation.

It is conceivable that tungsten is incorporated into metalloenzymes in obligate anaerobic bacteria; however, either tungsten-inhibited metalloenzymes were dispensable for overall fitness of most obligate anaerobic bacteria or incorporation of tungsten did not affect metalloenzyme activity. Notably, in the *Il10*/AOM model, tungstate treatment decreased the abundance of members of the phylum Verrucomicrobia. The genome of a member of the phylum Verrucomicrobia was sequenced and encodes at least one putative formate dehydrogenase, a putative molybdenum uptake system (ABC transporter), and genes predicted to be involved in the biosynthesis of a MoCo ([@bib39]). Another sequenced member of the phylum Verrucomicrobia encodes a limited number of genes involved in the biosynthesis of a MoCo (ATCC BAA-835; GenBank accession no. [CP001071.1](CP001071.1)). It is conceivable that erroneous uptake and incorporation of tungsten into a MoCo abolishes formate dehydrogenase activity in Verrucomicrobia members, thus decreasing their abundance in the gut microbiota. However, this does not appear to be a conserved mechanism, as Verrucomicrobia populations were not affected by tungstate in the AOM/DSS model ([Fig. 1 E](#fig1){ref-type="fig"}).

Curiously, hyperthermophilic archaea, methanogens, and environmental bacteria express a variety of tungstoenzymes with oxidoreductase activity ([@bib47]). In these enzymes, tungsten is bound by a molybdopterin cofactor or a molybdopterin derivative ([@bib63]; [@bib84]; [@bib42]). In some instances, tungsten can be functionally replaced by molybdenum. However, hyperthermophilic archaea appear to be strictly dependent on tungsten ([@bib53]), mirroring the strict dependence of Enterobacteriaceae on molybdenum in their respiratory metalloenzymes.

Microbial dysbiosis frequently occurs as a consequence of mucosal inflammation ([@bib110]). Conversely, experiments in mouse models suggest that a dysbiotic microbiota can instigate or worsen gut inflammation in some instances. Transfer of a dysbiotic microbiota into genetically susceptible mice is sufficient to trigger colitis ([@bib30]; [@bib85]), and the experimental colonization of mice with human AIEC isolates is sufficient to induce chronic colitis and fibrosis ([@bib12]; [@bib90]). The molecular mechanisms of how Enterobacteriaceae family members instigate inflammation in the setting of IBD are incompletely understood, but possibly involve a mislocalization of bacteria. AIEC strains frequently form biofilms in close proximity to the epithelium and invade nonphagocytic cells. Ileal epithelial cells in Crohn's disease patients express higher levels of carcinoembryonic antigen-related cell adhesion molecule 6, which serves as the receptor for type 1 fimbriae expressed by AIEC ([@bib6]; [@bib4]; [@bib3]). In our study, we found that tungstate administration not just reduced population levels of the murine AIEC strain NC101 in the gut lumen, but also decreased the number of tissue-associated bacteria and DNA damage in the intestinal epithelium. It should be noted that tungstate treatment did not deplete Gammaproteobacteria entirely from gut microbial communities, but a small population remained throughout the entire experiment. In fact, a complete eradication of Gammaproteobacteria may not be desirable, as these commensals contribute to colonization resistance against enteric pathogens through nutritional competition and release of antibacterial toxins ([@bib43]; [@bib22]; [@bib83]).

One mechanism of how microbial community members promote tumorigenesis is through the release of genotoxins in the intestinal tract ([@bib2]). In principle, probiotic bacterial strains could be used to outcompete genotoxic bacteria from the gut ecosystem. A recent report showed that microcins produced by the probiotic *E. coli* strain Nissle 1917 limit the expansion other Enterobacteriaceae during intestinal inflammation ([@bib83]), and one could speculate that Nissle 1917 could be used to eradicate genotoxin-producing Enterobacteriaceae. However, the Nissle 1917 genome encodes a functional *pks* synthesis island, and its genotoxicity cannot be disassociated from the probiotic effect ([@bib67]), suggesting that care must be taken when developing bacterial probiotics.

Other strategies have aimed to inhibit proinflammatory and protumoral properties of genotoxic *E. coli* strains. A recent study reported that inhibition of bacterial quorum sensing in flagellated AIEC strains reduces gut colonization by these strains and improves AIEC-driven intestinal inflammation ([@bib79]). In addition, small molecule inhibitors of colibactin biosynthesis have been developed ([@bib19]). Administration of these inhibitors significantly reduces colibactin-driven CAC progression in preclinical models ([@bib19]). In our study, we analyzed the effect of tungstate on reducing tumor incidence in a model of CAC in which tumorigenesis was in part driven by colibactin. Interestingly, the effect size of tungstate on tumor numbers was more pronounced than the contribution of colibactin alone ([Fig. 3](#fig3){ref-type="fig"}). This outcome is consistent with a scenario in which tungstate decreases tumor formation by acting on chronic inflammation and local colibactin production, both of which are dependent on luminal and mucosa-associated populations of the genotoxin-producing *E. coli*.

The adenoma-carcinoma sequence in FAP is thought to be an accelerated variant of most sporadic cancers, which are also defective for APC in most instances ([@bib41]). Enterotoxigenic *B. fragilis* enhances polyp formation in mouse models of FAP (*Apc^Min+/−^* mice; [@bib109]; [@bib16]; [@bib21]). Furthermore, tumor formation is magnified by *F. nucleatum* through the recruitment of tumor-infiltrating myeloid cells ([@bib49]). *B. fragilis* and *F. nucleatum* perform only a rudimentary type of anaerobic respiration, i.e., fumarate reduction, and the fumarate reductases expressed by these bacteria are not predicted to require molybdenum or a MoCo ([@bib56]; [@bib45]; [@bib65]). In line with these considerations, we found that tungstate did not impact polyp formation in *Apc^Min+/−^* mice. As such, our strategy of targeting the inflammation-associated bloom of Enterobacteriaceae family members is most applicable to high-risk populations with chronic colitis as one facet of a personalized medicine approach ([@bib82]). In summary, our experiments demonstrate that it is feasible to specifically target the metabolism of malignancy-promoting Enterobacteriaceae in the gut microbiota to reduce the risk of CAC development.

Materials and methods {#s10}
=====================

Bacterial strains {#s11}
-----------------

The *E. coli* strains used in this study are listed in Table S2. NC101 ([@bib70]) and *E. coli* MP13 ([@bib51]) strains were obtained from Dr. R. Balfour Sartor (University of North Carolina, Chapel Hill, NC) and Dr. Mark Goulian (University of Pennsylvania, Philadelphia, PA), respectively. All strains were routinely propagated in Luria-Bertani (LB) broth or on LB agar plates at 37°C with aeration. When appropriate, the following antibiotics were added: 20 µg/ml tetracycline, 100 µg/ml carbenicillin, and 100 µg/ml kanamycin. To facilitate recovery from fecal material, the NC101 wild-type was transformed with the plasmid pWSK29 ([@bib100]). The resulting strain, NC101(pWSK29), was used for all experiments and is referred to as NC101 throughout the text. Similarly, for the experiment shown in Fig. S1 (A and B), the *E. coli* Nissle wild-type was carrying pWSK29, while the Δ*moaA* mutant (SW930) and the Δ*narZ* Δ*narG* Δ*napA* mutant (SW1029) were marked with pWSK129 ([@bib36]; [@bib91]; [@bib107]; [@bib9]; [@bib40]; [@bib114]).

Construction of plasmids {#s12}
------------------------

Standard molecular cloning techniques ([@bib81]) or Gibson Assembly Cloning procedure (New England Biolabs) were used to construct plasmids. The flanking regions of the NC101 *pks* island were amplified and ligated into pGP706 to give rise to pWZ98. Plasmid inserts were verified by Sanger sequencing. All the plasmids and primers used in this study are listed in Tables S2 and S3.

Construction of mutants by allelic exchange {#s13}
-------------------------------------------

The pGP706-based suicide plasmid pWZ98 was routinely propagated in DH5α λ*pir* ([@bib69]). pWZ98 was then introduced into the *E. coli* strain NC101 via bacterial conjugation using S17-1 λ*pir* as the donor ([@bib89]; [@bib107]). LB plates containing appropriate antibiotics were used to select for exconjugants with the suicide plasmid integrated into the chromosome. Sucrose plates (8 g/liter nutrient broth base, 5% sucrose, 15 g/liter agar) were used to select for the second crossover event, which leads to the unmarked deletion of the gene of interest. pWZ98 was used to delete the *pks* island in *E. coli* strain NC101, creating WZ140. Deletion of the target gene was confirmed by PCR.

Animal experimentation {#s14}
----------------------

All experiments involving mice were approved by the Institutional Animal Care and Use Committee at University of Texas Southwestern Medical Center. Both male and female mice were analyzed, and no significant differences were noted. An approximately equal representation of male and female mice was sought. The number of individual animals per group is noted in each figure. Unless noted otherwise, animals had ad libitum access to autoclaved drinking water and irradiated rodent diet (Teklad global 16% protein 2916; Envigo). Room lighting was on a 12-h light/dark cycle. Animals were housed in individually ventilated cages. All treatments occurred in the designated animal facility. Animals that had to be euthanized for humane reasons before reaching the predetermined time points were excluded from the analysis.

DSS/AOM model and sodium tungstate treatment {#s15}
--------------------------------------------

C57BL/6J wild-type mice, obtained from the Jackson Laboratory, were bred under specific pathogen--free conditions at University of Texas Southwestern Medical Center. 7--9-wk-old mice were semirandomly assigned into treatment groups before the experiment. AOM (Sigma-Aldrich) was injected i.p. at a dosage of 20 mg/kg. 1 wk after AOM injection, the drinking water was replaced with 2 mg/ml streptomycin solution for 2 d. Mice were then inoculated with 10^9^ CFU of the indicated *E. coli* strain or remained uninfected. In the competitive colonization experiments, animals were inoculated with an equal mixture of 5 × 10^8^ CFU of wild-type *E. coli* Nissle 1917 strain and 5 × 10^8^ CFU of indicated mutant. 1 d after inoculation, the drinking water was replaced with filter-sterilized water (mock treatment), a filter-sterilized 2% (wt/vol) DSS solution (relative molecular mass 40,000; Alfa Aesar), or a filter-sterilized solution of 2% (wt/vol) DSS + 0.2% (wt/vol) sodium tungstate solution (Sigma-Aldrich). After 7 d, the drinking solution was replaced with either filter-sterilized water or filter-sterilized 0.2% (wt/vol) sodium tungstate for 2 wk. This treatment was repeated three times in total (see [Fig. 1 A](#fig1){ref-type="fig"}). Fecal pellets were collected at the indicated time points. After euthanasia, colon length was measured, and colons were opened longitudinally. Colonic tissue was collected, flash frozen, and stored at −80°C for subsequent mRNA and protein expression analysis. The remaining colonic and cecal tissue was fixed in 40 ml of phosphate-buffered 4% paraformaldehyde (Electron Microscopy Science) at 4°C overnight. Fixed tissue is further washed and stored in 70% ethanol solution. Images of the entire colons were captured using a STEMI 2000-c dissecting microscope (Zeiss) through AxioVision AxioVs40 software (version 4.8.1.0). Fecal material and colonic content were harvested in sterile PBS and the bacterial load of the *E. coli* strains was enumerated by plating on LB plates supplemented with appropriate antibiotics. In some experiments, fecal samples were not collected to minimize the impact of stress on experimental outcomes. Tissues from all experiments were collected and analyzed for tumor incidence. *E. coli* NC101 and Nissle 1917 strains were differentially marked with the low-copy-number plasmids pWSK29 or pWSK129 to facilitate bacterial recovery from biological samples ([@bib107]).

AOM/*Il10* model {#s16}
----------------

*Il10*-deficient mice ([@bib50]), originally obtained from the Jackson Laboratory (B6.129P2-*Il10*^tm1Cgn^/J, stock \#002251), were bred in the University of Texas Southwestern Medical Center facility. 8--10-wk-old mice were randomly assigned into cages before the experiment. AOM (Sigma-Aldrich) was injected i.p. at a dosage of 20 mg/kg. 1 wk after AOM injection, the drinking water was replaced with 2 mg/ml streptomycin solution for 2 d. Mice were then inoculated with 10^9^ CFU of the indicated *E. coli* strain. Piroxicam-supplemented diet (100 ppm; Envigo custom diet) was given after inoculation until the end of the experiment (38 d after the initial AOM injection). Sample collection and processing were performed as described above.

*APC^Min^*^+/−^ model {#s17}
---------------------

7--9-wk-old *APC^Min+/−^* mice were semirandomly assigned into treatment groups before the experiment. 1 d after randomization, the drinking water was replaced with a filtered-sterilized 2 mg/ml streptomycin solution for 2 d. Mice were then inoculated with 10^9^ CFU of the *E. coli* strain NC101. The drinking solution was replaced with either filter-sterilized water (mock-treatment) or filter-sterilized 0.02% (wt/vol) sodium tungstate for 4 wk (see Fig. S5 A). Sample collection and processing were performed as described above.

*APC^Min+/−^*/DSS model {#s18}
-----------------------

7--9-wk-old *APC^Min+/−^* mice were semirandomly assigned into treatment groups before the experiment. 1 d after randomization, the drinking water was replaced with a filter-sterilized 2% (wt/vol) DSS solution (relative molecular mass 40,000; Alfa Aesar). 7 d later, the drinking water was replaced with a filtered-sterilized 2 mg/ml streptomycin solution for 2 d. Mice were then inoculated with 10^9^ CFU of the *F. nucleatum* strain ATCC 23726. The drinking solution was replaced with either filter-sterilized water (mock treatment) or filter-sterilized 0.02% (wt/vol) sodium tungstate for 4 wk (see Fig. S5 D). Sample collection and processing were performed as described above.

Colonocyte isolation {#s19}
--------------------

C57BL/6J wild-type mice were injected i.p. with AOM at a dosage of 20 mg/kg. 1 wk after AOM injection, mice were treated with streptomycin and inoculated with 10^9^ CFU of the colibactin-producing *E. coli* strain NC101. Mice were treated with DSS or DSS + sodium tungstate or left untreated for 7 d and allowed to recover for 4 d. After euthanasia, large intestine was collected, and the colonocytes were harvested using a modified procedure originally described by [@bib78]. Briefly, colon was opened longitudinally and washed extensively to remove luminal content. The colon was then placed in 2 ml of Krebs-Ringer bicarbonate (Ca^2+^ free) buffer (1.8 g/liter [d]{.smallcaps}-glucose, 0.0468 g/liter MgCl~2~, 0.34 g/liter KCl, 7 g/liter NaCl, 0.1 g/liter Na~2~HPO~4~, 0.18 g/liter NaH~2~PO~4~, and 1.26 g/liter NaHCO~3~, pH 7.4) supplemented with 1 mM DTT and 10 mM EDTA (pH 8.0). The tissue was shaken at 220 rpm and 37°C for 40 min. Colonocytes were collected by passing the tissue through a 70-µm cell strainer, and the flow-through cells were centrifuged at 300 *g* for 5 min. Red blood cells were lysed by incubating cells in ammonium-chloride-potassium lysis buffer (8.02 g/liter NH~4~Cl, 1 g/liter KHCO~3~, and 0.037 mg/liter EDTA, pH 7.4) for 1 min. Colonocytes were washed two more times with Ca^2+^-free Krebs-Ringer bicarbonate buffer before preservation with RNAlater (Qiagen) to stabilize cellular RNA. Total RNA was subsequently extracted using RNeasy Mini Kit (Qiagen), and residual DSS contaminants in RNA samples were removed using Dynabeads mRNA Direct Kit (Life Technologies).

16S rDNA amplicon sequencing and analysis {#s20}
-----------------------------------------

Fecal pellets or colonic contents were collected, and DNA extraction was performed using the MoBio PowerFecal kit (MoBio Laboratories), followed by potassium chloride precipitation to remove residual DSS contaminants ([@bib40]). The V4 region of 16S rDNA of the purified DNA was amplified with the 515f-806R primer pair. The library was purified and quantified with the 2200 TapeStation (Agilent) and sequenced with the Illumina MiSeq platform, generating 250-bp (AOM/DSS model) or 300-bp (*Il10*/AOM model) paired-end reads. Sequence alignment, operational taxonomic units picking against the Silva database (version 128, released on February 6, 2017; [@bib75]), clustering, phylogenetic and taxonomic profiling, ANOSIM analysis, and the analysis of β diversity (principal component analysis) on the demultiplexed sequences were performed with the Quantitative Insights into Microbial Ecology software package (version 1.91; [@bib11]; [@bib97]). The bacterial 16S rDNA and metagenomics sequencing reads generated and analyzed during the current study are available at the European Bioinformatics Institute repository under accession nos. [PRJEB29047](PRJEB29047) and [PRJEB32761](PRJEB32761).

Immunofluorescence staining and quantification {#s21}
----------------------------------------------

Paraffin-embedded, transverse sections of colon tissue were hybridized overnight with 2 µM fluorescence in situ hybridization probe specific for Enterobacteriaceae members at 55°C in hybridization buffer ([@bib46]). The slides were subsequently washed three times with fluorescence in situ hybridization wash buffer and blocked with 4% bovine serum albumin in PBS for 30 min at RT. Blocked slides were stained with anti-phosphorylated γ-H2AX antibody (\#9718S; Cell Signaling) and subsequently with Alexa Fluor 488--conjugated anti-rabbit antibody (\#4412; Cell Signaling). Tile images were captured using an LSM780 confocal microscope (Zeiss) and stitched using Imaris software 8.2 (Bitplane AG). Quantification of tissue-associated *E. coli* burden as well DNA damage was performed using the spot and surface function of Imaris software 8.2. In each tissue, 6,688 to 23,809 cells were counted, and only fluorescent objects with a diameter \>6 µm (average diameter of mammalian cell nucleus) were counted to eliminate contamination and nonspecific staining.

Quantification of mRNA levels in intestinal tissue {#s22}
--------------------------------------------------

The relative transcription levels of *Nos2*, *Cxcl1*, *Cxcl2*, *Il17*, *Ifng*, and *Tnfa* genes were determined by quantitative RT-PCR as described previously ([@bib106]). Briefly, colonic tissue was homogenized using a Mini beadbeater (Biospec Products). The TRI reagent method was performed to extract RNA from the homogenized tissue (Molecular Research Center). Residual DSS contaminants in RNA samples were removed using Dynabeads mRNA Direct Kit (Life Technologies). TaqMan reverse transcription reagents (Life Technologies) were used to generate cDNA and real-time PCR was performed using SYBR Green (Life Technologies). Data were acquired in a QuantStudio 6 Flex instrument (Life Technologies) and analyzed using the comparative Ct method. The primers of the gene of interest (listed in Table 3; [@bib68]; [@bib32]; [@bib104]; [@bib102]) were added at a final concentration of 250 nM. The respective levels of *Gapdh* mRNA were used for target gene transcription normalization.

Quantification and statistical analysis {#s23}
---------------------------------------

Unless noted otherwise, data analysis was performed in GraphPad Prism v7.0c. Values of bacterial population sizes, competitive indices, fold changes in mRNA levels, and normalized colon length were transformed by the natural logarithm before statistical analysis. Time course experiments of *E. coli* populations were analyzed by two-way ANOVA and a post hoc Tukey's multiple comparison test. A Student's *t* test was used for all other log-transformed data, while tumor incidence was compared using the Mann--Whitney *U* test, as indicated in the figure legends. A P value \<0.05 was considered significant.

Online supplemental material {#s24}
----------------------------

Fig. S1 describes the impact of tungstate treatment on *E. coli* fitness and the dynamics of gut microbial communities, and Fig. S2 depicts the analysis of colitis markers in the AOM/DSS colitis model. Fig. S3 analyzes the colonization of NC101 and host inflammatory responses in a murine model. Fig. S4 shows host DNA damage and inflammatory responses in a colibactin-driven tumorigenesis model. Fig. S5 explores the impact of tungstate treatment on *Apc*^Min+/−^ models of tumorigenesis in the large intestine. Scores of individual samples on the intestinal inflammation and tumor histology are included in Table S1. Strains and plasmids used in this study are listed in Table S2. All primers used in this study are listed in Table S3.
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